Global Down Syndrome

Issue 3 of 4 2017

Issue link: https://viewer.e-digitaledition.com/i/866792

Contents of this Issue

Navigation

Page 9 of 31

he read a paper by late angiogenesis researcher Judah Folkman, M.D., of Harvard University. Dr. Folkman's research showed that solid tumors depend on newly formed blood vessels for their growth. Overexpression of chemical signals that block the process — known as angiogenesis inhibitors — may occur in people with Down syndrome. According to Dr. Galambos, that protective property may come with a downside in the form of pulmonary underdevelopment and dysfunction. "Chromosome 21 has many genes that act as anti-vascular or anti- angiogenic factors," he said. "In people with Down syndrome, there is an excess of anti-angiogenic factors that could significantly block normal vessel development in all organs, including the lungs. Our goal is to explore a previously unrecognized role of the chromosome 21-specific anti-angiogenic factors that may lead to lung immaturity and increase the risk for severe PAH in infants and children with Down syndrome." MODELING ANGIOGENESIS Using banked lung tissue samples, Dr. Galambos and colleagues created a number of different models to re-create angiogenesis and observe the effects of its impairment. "We measured the messenger RNA expression levels of 84 angiogenesis- related genes in Down syndrome fetal lung samples and typical controls, and we also looked at microscopic signs of impaired lung vascular growth," Dr. Galambos said. "Not only did we discover that three potent chromosome 21-related anti-angiogenic factors are overexpressed significantly in the lung in utero, we also identified two other potent anti-angiogenic factors with significant overexpression that were unrelated to chromosome 21. Significantly, our analysis showed features of impaired vascular growth in these lungs." The next step for Dr. Galambos and his group was to develop cell-culture and animal models in which they could further test the effects of anti-angiogenesis. "There are Down syndrome mouse models that carry three copies of portions of chromosome 21," Dr. Galambos said. "We are excited that we are able to show, for the first time, that one of these models develops features characteristic of impaired lung development seen in the lungs of humans with Down syndrome." Dr. Galambos plans to use the mouse model to further investigate the unique ways that Down syndrome affects angiogenesis, as well as the anti-angiogenic pathways that may play a role in abnormal pulmonary development and function. A 2017 Crnic Institute Grand Challenge Grant underwritten by the Global Down Syndrome Foundation will support his work. Dr. Galambos believes this research could produce findings — and point the way to novel therapies — that are applicable not only to patients with Down syndrome, but also to individuals in the general population with pulmonary hypoplasia and PAH. THE NEXT FRONTIER? Even as he explores the role of angiogenic impairment in lung disease, Dr. Galambos is pondering the possibility that it could also affect cognition in individuals with Down syndrome. "It is well known that proper angiogenic signals are required for optimal nerve growth, supporting intellectual development," he said. "In Down syndrome and Alzheimer's disease, nerve development and function are compromised. It has been shown that the three- dimensional vascular network of the brain is impaired in Alzheimer's disease. It's a realistic possibility that impaired angiogenesis not only causes underdeveloped lungs and PAH, but may also affect the development and function of neural networks of the brain in people with Down syndrome." Dr. Galambos believes a future in which clinicians use angiogenic therapies to treat lung disease and improve cognitive function in people with Down syndrome is possible — and he is doing his part to accelerate its arrival. Csaba Galambos, M.D., Ph.D., a pediatric pathologist in the Children's Hospital Colorado Department of Pathology and Laboratory Medicine and Associate Professor of Pathology at the University of Colorado School of Medicine, has received many notable grants to further his research into the links between lung disease and Down syndrome, including: 2014–2016 Jérôme Lejeune Foundation Grant, $39,000 "Role of Impaired Angiogenesis in the Pathogenesis of Severe Cardiopulmonary Disease in Children with Down Syndrome" Role: Principal Investigator 2017 Crnic Grand Challenge Grant, $50,000 "Overexpression of Anti-angiogenic Genes Impairs Lung Development in Dp16 Mice" 2017 ISSUE 3 OF 4 • DOWN SYNDROME WORLD 10

Articles in this issue

Archives of this issue

view archives of Global Down Syndrome - Issue 3 of 4 2017